Scott W W, Gibbons R P, Johnson D E, Prout G R, Schmidt J D, Saroff J, Murphy G P
J Urol. 1976 Aug;116(2):211-3. doi: 10.1016/s0022-5347(17)58751-0.
The response and duration of survival were evaluated for patients with stage D relapsing prostatic cancer who were randomized to cyclophosphamide (cytoxan), 5-fluorouracil (5-FU) or standard therapy, or to subsequent chemotherapies. The chemotherapies on initial randomization were superior to the standard therapy in the number of responders and duration of response. Survival was longer for responders (stable or partial regression) on chemotherapy by comparison to responders (stable only) on standard therapy. The survival for patients receiving initial and crossover chemotherapy was significantly improved for patients who responded to therapy. Chemotherapy of advanced relapsing stage D prostatic cancer is more beneficially treated by specific chemotherapy as shown in this randomized study.
对随机接受环磷酰胺（癌得星）、5-氟尿嘧啶（5-FU）或标准疗法，或后续化疗的D期复发性前列腺癌患者的反应和生存持续时间进行了评估。初始随机分组时的化疗在缓解者数量和缓解持续时间方面优于标准疗法。与接受标准疗法的缓解者（仅病情稳定）相比，接受化疗的缓解者（病情稳定或部分缓解）生存期更长。对治疗有反应的患者，接受初始和交叉化疗后的生存期显著改善。如本随机研究所示，晚期复发性D期前列腺癌采用特定化疗更有益。
